In a recent news release, Qualcomm, Inc. (NASDAQ: QCOM), through subsidiary Qualcomm Life, Inc., announced a new collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. to develop a connectivity solution for the RESPIMAT® inhaler, the platform inhaler for Boehringer Ingelheim’s family of respiratory therapies. The collaborative effort will aim to improve chronic obstructive pulmonary disease (COPD) treatment outcomes.
“Qualcomm Life is committed to powering the Internet of Medical Things to ultimately enable intelligent care to be delivered wherever the patient may be,” Rick Valencia, president of Qualcomm Life, stated in the news release. “We are excited to be collaborating with an industry leader like Boehringer Ingelheim to deliver a more seamless digital health experience that can enable their COPD patients to better manage their disease.”
As with most chronic diseases, proper adherence to treatment plans is essential to management of COPD symptoms and long-term health. Leveraging its medical-grade 2net™ Connectivity Platform, Qualcomm Life aims to develop the prototype for a compact, low-power, disposable module for Boehringer Ingelheim’s RESPIMAT inhaler that will collect data regarding adherence to daily treatment regimens and report to both health care providers and individuals who have been prescribed RESPIMAT medications. By providing the means to better track information regarding treatments, the collaboration could result in lower health care costs and fewer hospitalizations for people living with COPD.
“Boehringer Ingelheim is proud to join forces with Qualcomm Life, a global leader in wireless technologies, to bring the latest technology to our RESPIMAT inhaler with the goal of improving adherence to daily medicines that treat symptoms of COPD,” Ruchin Kansal, executive director and head of business innovation with Boehringer Ingelheim, added.
According to data from the American Lung Association (http://nnw.fm/9Qtq2), COPD is currently the third leading cause of death in the United States, trailing only heart disease and cancer. More than 11 million people living across the country have already been diagnosed with COPD, but an estimated 24 million additional people may have the disease without knowing it. This is because many people attribute the symptoms, such as shortness of breath and tiring easily, to aging. Although no cure currently exists for COPD, available treatments can be extremely effective if started in the disease’s early stages. With this in mind, the market potential for a connectivity solution for the RESPIMAT inhaler could be expansive.
For more information, visit www.Qualcomm.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
